JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wolfe, H. R.
Right arrow Articles by Waldman, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wolfe, H. R.
Right arrow Articles by Waldman, S. A.
Journal of Nuclear Medicine Vol. 43 No. 3 392-399
© 2002 by Society of Nuclear Medicine


Basic Science Investigations

In Vivo Imaging of Human Colon Cancer Xenografts in Immunodeficient Mice Using a Guanylyl Cyclase C–Specific Ligand

Henry R. Wolfe, MS1, Marivi Mendizabal, PhD2, Elinor Lleong, BS1, Alan Cuthbertson, PhD3, Vinay Desai, PhD4, Shirley Pullan, PhD2, Dennis K. Fujii, PhD5, Matthew Morrison, PhD2, Richard Pither, PhD2 and Scott A. Waldman, MD, PhD6

1 Research and Development Department, Targeted Diagnostics & Therapeutics, Inc., West Chester, Pennsylvania
2 Research Department, Nycomed Amersham plc, Little Chalfont, Amersham, United Kingdom
3 Department of Synthetic Chemistry, Nycomed Amersham plc, Oslo, Norway
4 Biological Research, Nycomed Amersham Inc., Wayne, Pennsylvania
5 Biological Research, Nycomed Amersham plc, Durham, North Carolina
6 Departments of Medicine and Biochemistry and Molecular Pharmacology, Thomas Jefferson University, Philadelphia, Pennsylvania

Guanylyl cyclase C (GC-C) is a transmembrane receptor expressed by human intestinal cells and primary and metastatic colorectal adenocarcinomas but not by extraintestinal tissues or tumors. The Escherichia coli heat-stable enterotoxin analog, STa (5–18), is a 14–amino acid peptide that selectively binds to the extracellular domain of GC-C with subnanomolar affinity. This study examined the utility of a radiolabeled conjugate of STa (5–18) to selectively target and image extraintestinal human colon cancer xenografts in vivo in nude mice. Methods: The STa conjugate, ethoxyethyl-mercaptoacetamidoadipoylglycylglycine-STa (5–18) (NC100586), was synthesized and labeled with 99mTc to produce 99mTc-NC100586. This compound was intravenously administered to nude mice bearing human colon cancer xenografts, and specific targeting was evaluated by biodistribution and gamma camera imaging. Results: In CD-1 nude mice, biodistribution and scintigraphic imaging analyses showed selective uptake of 99mTc-NC100586 into human colon cancer xenografts that express GC-C but not into normal tissues that do not express GC-C. Similarly, 99mTc-NC100586 injected intravenously into CD-1 nude mice with human colon cancer hepatic metastases selectively accumulated in those metastases, and ~5-mm foci of tumor cells were visualized after ex vivo imaging of excised livers. Accumulation of 99mTc-NC100586 in human colon cancer xenografts reflected binding to GC-C because 99mTc-NC100588, an inactive analog that does not bind to GC-C, did not selectively accumulate in cancer xenografts compared with normal tissues. Also, coadministration of excess unlabeled STa (5–18) prevented accumulation of 99mTc-NC100586 in human colon cancer xenografts. Furthermore, 99mTc-NC100586 did not selectively accumulate in Lewis lung tumor xenografts, which do not express GC-C. Conclusion: This study showed that intravenously administered STa (5–18) selectively recognizes and binds to GC-C expressed by human colon cancer cells in vivo. Also shown was the ability to exploit this selective interaction to target imaging agents to extraintestinal human colon tumors in nude mice. These results suggest the utility of STa and GC-C for the development of novel targeted imaging and therapeutic agents with high specificity for metastatic colorectal tumors in humans.

Key Words: guanylyl cyclase C • STa • colorectal cancer • enterotoxin




This article has been cited by other articles:


Home page
Anticancer ResHome page
D. LIU, D. OVERBEY, L. D. WATKINSON, S. DAIBES-FIGUEROA, T. J. HOFFMAN, L. R. FORTE, W. A. VOLKERT, and M. F. GIBLIN
In Vivo Imaging of Human Colorectal Cancer Using Radiolabeled Analogs of the Uroguanylin Peptide Hormone
Anticancer Res, October 1, 2009; 29(10): 3777 - 3783.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. E. Snook, B. J. Stafford, P. Li, G. Tan, L. Huang, R. Birbe, S. Schulz, M. J. Schnell, M. Thakur, J. L. Rothstein, et al.
Guanylyl Cyclase C-Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity
J Natl Cancer Inst, July 2, 2008; 100(13): 950 - 961.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. M. Pitari, R. I. Baksh, D. M. Harris, P. Li, S. Kazerounian, and S. A. Waldman
Interruption of Homologous Desensitization in Cyclic Guanosine 3',5'-Monophosphate Signaling Restores Colon Cancer Cytostasis by Bacterial Enterotoxins
Cancer Res., December 1, 2005; 65(23): 11129 - 11135.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.